Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Research

Oncologic relevance of genetic alterations in sporadic synchronous and solitary colorectal cancer: a retrospective multicenter study

Authors: Il Tae Son, Minsung Kim, Bo Young Oh, Min Jeong Kim, Sang Nam Yoon, Jun Ho Park, Byung Chun Kim, Jong Wan Kim

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Oncologic impact of genetic alteration across synchronous colorectal cancer (CRC) still remains unclear. This study aimed to compare the oncologic relevance according to genetic alteration between synchronous and solitary CRC with performing systematic review.

Methods

Multicenter retrospective analysis was performed for CRC patients with curative resection. Genetic profiling was consisted of microsatellite instability (MSI) testing, RAS (K-ras, and N-ras), and BRAF (v-Raf murine sarcoma viral oncogene homolog B1) V600E mutation. Multivariate analyses were conducted using logistic regression for synchronicity, and Cox proportional hazard model with stage-adjusting for overall survival (OS) and disease-free survival (DFS).

Results

It was identified synchronous (n = 36) and solitary (n = 579) CRC with similar base line characteristics. RAS mutation was associated to synchronous CRC with no relations of MSI and BRAF. During median follow up of 77.8 month, Kaplan–meier curves showed significant differences according to MSI-high for OS, and in RAS, and BRAF mutation for DFS, respectively. In multivariable analyses, RAS and BRAF mutation were independent factors (RAS, HR = 1.808, 95% CI = 1.18–2.77, p = 0.007; BRAF, HR = 2.417, 95% CI = 1.32–4.41, p = 0.004). Old age was independent factor for OS (HR = 3.626, 95% CI = 1.09–12.00, p = 0.035).

Conclusion

This study showed that oncologic outcomes might differ according to mutation burden characterized by RAS, BRAF, and MSI between synchronous CRC and solitary CRC. In addition, our systematic review highlighted a lack of data and much heterogeneity in genetic characteristics and survival outcomes of synchronous CRC relative to that of solitary CRC.
Literature
1.
go back to reference Bae JM, Cho NY, Kim TY, Kang GH. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors. Dis Colon Rectum. 2012;55(2):181–90.CrossRefPubMed Bae JM, Cho NY, Kim TY, Kang GH. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors. Dis Colon Rectum. 2012;55(2):181–90.CrossRefPubMed
2.
go back to reference Bae JM, Cho N-Y, Kim T-Y, Kang GH. Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Cancers: Heterogeneity of Clinical Outcome Depending on Microsatellite Instability Status of Individual Tumors. Diseases of the Colon & Rectum. 2012;55(2):181–90.CrossRef Bae JM, Cho N-Y, Kim T-Y, Kang GH. Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Cancers: Heterogeneity of Clinical Outcome Depending on Microsatellite Instability Status of Individual Tumors. Diseases of the Colon & Rectum. 2012;55(2):181–90.CrossRef
3.
go back to reference Lee BC, Yu CS, Kim J, Lee JL, Kim CW, Yoon YS, et al. Clinicopathological features and surgical options for synchronous colorectal cancer. Medicine. 2017;96(9): e6224.CrossRefPubMedPubMedCentral Lee BC, Yu CS, Kim J, Lee JL, Kim CW, Yoon YS, et al. Clinicopathological features and surgical options for synchronous colorectal cancer. Medicine. 2017;96(9): e6224.CrossRefPubMedPubMedCentral
4.
go back to reference Wang X, Fang H, Cheng Y, Li L, Sun X, Fu T, et al. The molecular landscape of synchronous colorectal cancer reveals genetic heterogeneity. Carcinogenesis. 2018;39(5):708–18.CrossRefPubMedPubMedCentral Wang X, Fang H, Cheng Y, Li L, Sun X, Fu T, et al. The molecular landscape of synchronous colorectal cancer reveals genetic heterogeneity. Carcinogenesis. 2018;39(5):708–18.CrossRefPubMedPubMedCentral
5.
go back to reference Hu H, Zhang Q, Huang R, Gao Z, Yuan Z, Tang Q, et al. Genomic Analysis Reveals Heterogeneity Between Lesions in Synchronous Primary Right-Sided and Left-Sided Colon Cancer. Front Mol Biosci. 2021;8: 689466.CrossRefPubMedPubMedCentral Hu H, Zhang Q, Huang R, Gao Z, Yuan Z, Tang Q, et al. Genomic Analysis Reveals Heterogeneity Between Lesions in Synchronous Primary Right-Sided and Left-Sided Colon Cancer. Front Mol Biosci. 2021;8: 689466.CrossRefPubMedPubMedCentral
6.
go back to reference Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology. 2009;137(5):1609-20 e1-3.CrossRefPubMed Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology. 2009;137(5):1609-20 e1-3.CrossRefPubMed
7.
go back to reference Dykes SL, Qui H, Rothenberger DA, Garcia-Aguilar J. Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer. Cancer. 2003;98(1):48–54.CrossRefPubMed Dykes SL, Qui H, Rothenberger DA, Garcia-Aguilar J. Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer. Cancer. 2003;98(1):48–54.CrossRefPubMed
8.
go back to reference Lam AK, Carmichael R, Gertraud Buettner P, Gopalan V, Ho YH, Siu S. Clinicopathological significance of synchronous carcinoma in colorectal cancer. Am J Surg. 2011;202(1):39–44.CrossRefPubMed Lam AK, Carmichael R, Gertraud Buettner P, Gopalan V, Ho YH, Siu S. Clinicopathological significance of synchronous carcinoma in colorectal cancer. Am J Surg. 2011;202(1):39–44.CrossRefPubMed
9.
go back to reference Mulder SA, Kranse R, Damhuis RA, de Wilt JH, Ouwendijk RJ, Kuipers EJ, et al. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. Cancer Epidemiol. 2011;35(5):442–7.CrossRefPubMed Mulder SA, Kranse R, Damhuis RA, de Wilt JH, Ouwendijk RJ, Kuipers EJ, et al. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. Cancer Epidemiol. 2011;35(5):442–7.CrossRefPubMed
10.
go back to reference van Leersum NJ, Aalbers AG, Snijders HS, Henneman D, Wouters MW, Tollenaar RA, et al. Synchronous colorectal carcinoma: a risk factor in colorectal cancer surgery. Dis Colon Rectum. 2014;57(4):460–6.CrossRefPubMed van Leersum NJ, Aalbers AG, Snijders HS, Henneman D, Wouters MW, Tollenaar RA, et al. Synchronous colorectal carcinoma: a risk factor in colorectal cancer surgery. Dis Colon Rectum. 2014;57(4):460–6.CrossRefPubMed
11.
go back to reference Kato T, Alonso S, Muto Y, Noda H, Miyakura Y, Suzuki K, et al. Clinical characteristics of synchronous colorectal cancers in Japan. World J Surg Oncol. 2016;14(1):272.CrossRefPubMedPubMedCentral Kato T, Alonso S, Muto Y, Noda H, Miyakura Y, Suzuki K, et al. Clinical characteristics of synchronous colorectal cancers in Japan. World J Surg Oncol. 2016;14(1):272.CrossRefPubMedPubMedCentral
12.
go back to reference Arakawa K, Hata K, Nozawa H, Kawai K, Tanaka T, Nishikawa T, et al. Prognostic Significance and Clinicopathological Features of Synchronous Colorectal Cancer. Anticancer Res. 2018;38(10):5889–95.CrossRefPubMed Arakawa K, Hata K, Nozawa H, Kawai K, Tanaka T, Nishikawa T, et al. Prognostic Significance and Clinicopathological Features of Synchronous Colorectal Cancer. Anticancer Res. 2018;38(10):5889–95.CrossRefPubMed
13.
go back to reference Latournerie M, Jooste V, Cottet V, Lepage C, Faivre J, Bouvier AM. Epidemiology and prognosis of synchronous colorectal cancers. Br J Surg. 2008;95(12):1528–33.CrossRefPubMed Latournerie M, Jooste V, Cottet V, Lepage C, Faivre J, Bouvier AM. Epidemiology and prognosis of synchronous colorectal cancers. Br J Surg. 2008;95(12):1528–33.CrossRefPubMed
14.
15.
go back to reference Yang J, Peng JY, Chen W. Synchronous colorectal cancers: a review of clinical features, diagnosis, treatment, and prognosis. Dig Surg. 2011;28(5–6):379–85.CrossRefPubMed Yang J, Peng JY, Chen W. Synchronous colorectal cancers: a review of clinical features, diagnosis, treatment, and prognosis. Dig Surg. 2011;28(5–6):379–85.CrossRefPubMed
16.
go back to reference Lam AK, Chan SS, Leung M. Synchronous colorectal cancer: clinical, pathological and molecular implications. World J Gastroenterol. 2014;20(22):6815–20.CrossRefPubMedPubMedCentral Lam AK, Chan SS, Leung M. Synchronous colorectal cancer: clinical, pathological and molecular implications. World J Gastroenterol. 2014;20(22):6815–20.CrossRefPubMedPubMedCentral
17.
go back to reference Hu H, Chang DT, Nikiforova MN, Kuan SF, Pai RK. Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis. Am J Surg Pathol. 2013;37(11):1660–70.CrossRefPubMed Hu H, Chang DT, Nikiforova MN, Kuan SF, Pai RK. Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis. Am J Surg Pathol. 2013;37(11):1660–70.CrossRefPubMed
18.
go back to reference Warps AK, Detering R, Dekker JWT, Tollenaar R, Tanis PJ, Dutch CA. A 10-Year Evaluation of Short-Term Outcomes After Synchronous Colorectal Cancer Surgery: a Dutch Population-Based Study. J Gastrointest Surg. 2021;25(10):2637–48.CrossRefPubMedPubMedCentral Warps AK, Detering R, Dekker JWT, Tollenaar R, Tanis PJ, Dutch CA. A 10-Year Evaluation of Short-Term Outcomes After Synchronous Colorectal Cancer Surgery: a Dutch Population-Based Study. J Gastrointest Surg. 2021;25(10):2637–48.CrossRefPubMedPubMedCentral
19.
go back to reference Konishi K, Shen L, Jelinek J, Watanabe Y, Ahmed S, Kaneko K, et al. Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila). 2009;2(9):814–22.CrossRefPubMed Konishi K, Shen L, Jelinek J, Watanabe Y, Ahmed S, Kaneko K, et al. Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila). 2009;2(9):814–22.CrossRefPubMed
20.
go back to reference Norrie MW, Hawkins NJ, Todd AV, Meagher AP, O’Connor TW, Ward RL. The role of hMLH1 methylation in the development of synchronous sporadic colorectal carcinomas. Dis Colon Rectum. 2002;45(5):674–80.CrossRefPubMed Norrie MW, Hawkins NJ, Todd AV, Meagher AP, O’Connor TW, Ward RL. The role of hMLH1 methylation in the development of synchronous sporadic colorectal carcinomas. Dis Colon Rectum. 2002;45(5):674–80.CrossRefPubMed
21.
go back to reference Giannini R, Lupi C, Loupakis F, Servadio A, Cremolini C, Sensi E, et al. KRAS and BRAF genotyping of synchronous colorectal carcinomas. Oncol Lett. 2014;7(5):1532–6.CrossRefPubMedPubMedCentral Giannini R, Lupi C, Loupakis F, Servadio A, Cremolini C, Sensi E, et al. KRAS and BRAF genotyping of synchronous colorectal carcinomas. Oncol Lett. 2014;7(5):1532–6.CrossRefPubMedPubMedCentral
23.
go back to reference Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105(15):1151–6.CrossRefPubMedPubMedCentral Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105(15):1151–6.CrossRefPubMedPubMedCentral
25.
go back to reference Huang CJ, Huang SH, Chien CC, Lee HH, Yang SH, Chang CC, et al. Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. Oncol Lett. 2016;12(6):4427–34.CrossRefPubMedPubMedCentral Huang CJ, Huang SH, Chien CC, Lee HH, Yang SH, Chang CC, et al. Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. Oncol Lett. 2016;12(6):4427–34.CrossRefPubMedPubMedCentral
26.
go back to reference de Cuba EM, Snaebjornsson P, Heideman DA, van Grieken NC, Bosch LJ, Fijneman RJ, et al. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. Int J Cancer. 2016;138(5):1139–45.CrossRefPubMed de Cuba EM, Snaebjornsson P, Heideman DA, van Grieken NC, Bosch LJ, Fijneman RJ, et al. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. Int J Cancer. 2016;138(5):1139–45.CrossRefPubMed
27.
go back to reference de Macedo MP, de Melo FM, Ribeiro Jda S, de Mello CA, de Souza Begnami MD, Soares FA, et al. RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions. Oncoscience. 2015;2(2):125–30.CrossRefPubMedPubMedCentral de Macedo MP, de Melo FM, Ribeiro Jda S, de Mello CA, de Souza Begnami MD, Soares FA, et al. RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions. Oncoscience. 2015;2(2):125–30.CrossRefPubMedPubMedCentral
28.
go back to reference Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329–59.CrossRefPubMed Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329–59.CrossRefPubMed
30.
go back to reference Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. J Clin Oncol. 2008;27(5):672–80.CrossRefPubMed Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. J Clin Oncol. 2008;27(5):672–80.CrossRefPubMed
31.
go back to reference Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med. 2013;369(11):1023–34.CrossRefPubMed Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med. 2013;369(11):1023–34.CrossRefPubMed
32.
go back to reference Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6(5):279–86.CrossRefPubMed Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6(5):279–86.CrossRefPubMed
33.
go back to reference Malesci A, Basso G, Bianchi P, Fini L, Grizzi F, Celesti G, et al. Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia. Br J Cancer. 2014;110(5):1228–35.CrossRefPubMedPubMedCentral Malesci A, Basso G, Bianchi P, Fini L, Grizzi F, Celesti G, et al. Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia. Br J Cancer. 2014;110(5):1228–35.CrossRefPubMedPubMedCentral
34.
go back to reference Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst. 2005;97(18):1317–9.CrossRefPubMed Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst. 2005;97(18):1317–9.CrossRefPubMed
35.
go back to reference Fukatsu H, Kato J, Nasu JI, Kawamoto H, Okada H, Yamamoto H, et al. Clinical characteristics of synchronous colorectal cancer are different according to tumour location. Dig Liver Dis. 2007;39(1):40–6.CrossRefPubMed Fukatsu H, Kato J, Nasu JI, Kawamoto H, Okada H, Yamamoto H, et al. Clinical characteristics of synchronous colorectal cancer are different according to tumour location. Dig Liver Dis. 2007;39(1):40–6.CrossRefPubMed
36.
go back to reference He W, Zheng C, Wang Y, Dan J, Zhu M, Wei M, et al. Prognosis of synchronous colorectal carcinoma compared to solitary colorectal carcinoma: a matched pair analysis. Eur J Gastroenterol Hepatol. 2019;31(12):1489–95.CrossRefPubMedPubMedCentral He W, Zheng C, Wang Y, Dan J, Zhu M, Wei M, et al. Prognosis of synchronous colorectal carcinoma compared to solitary colorectal carcinoma: a matched pair analysis. Eur J Gastroenterol Hepatol. 2019;31(12):1489–95.CrossRefPubMedPubMedCentral
37.
go back to reference Lawes DA, Pearson T, Sengupta S, Boulos PB. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers. Br J Cancer. 2005;93(4):472–7.CrossRefPubMedPubMedCentral Lawes DA, Pearson T, Sengupta S, Boulos PB. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers. Br J Cancer. 2005;93(4):472–7.CrossRefPubMedPubMedCentral
38.
go back to reference Kong P, Wu R, Lan Y, He W, Yang C, Yin C, et al. Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis. J Cancer. 2017;8(16):3296–308.CrossRefPubMedPubMedCentral Kong P, Wu R, Lan Y, He W, Yang C, Yin C, et al. Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis. J Cancer. 2017;8(16):3296–308.CrossRefPubMedPubMedCentral
39.
go back to reference Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013;45(4):346–56.CrossRefPubMed Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013;45(4):346–56.CrossRefPubMed
40.
go back to reference Wu M, Kim YS, Ryu HS, Choi SC, Kim KY, Park WC, et al. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis. Pathol Res Pract. 2020;216(1): 152791.CrossRefPubMed Wu M, Kim YS, Ryu HS, Choi SC, Kim KY, Park WC, et al. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis. Pathol Res Pract. 2020;216(1): 152791.CrossRefPubMed
Metadata
Title
Oncologic relevance of genetic alterations in sporadic synchronous and solitary colorectal cancer: a retrospective multicenter study
Authors
Il Tae Son
Minsung Kim
Bo Young Oh
Min Jeong Kim
Sang Nam Yoon
Jun Ho Park
Byung Chun Kim
Jong Wan Kim
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02937-7

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.